In a post hoc analysis of a randomized controlled trial of metformin in patients with obesity and proven coronary artery disease (248), metformin administration led to substantial and sustained elevations in circulating levels of GDF15. This evidence concerns the gene GDF15 and obesity due to melanocortin 4 receptor deficiency.